Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I got in 3 years ago: had 5.1MM shares, now have 69.
“Early”=DISASTER on this one
DILUTION. It has led to two consecutive R/Ss within less than two years (one haircut took away 150 shares and gave 1, while the most recent hacked away further by a 1:500 factor. It’s what they do…
Down, down (“Rock Lobster” playing in background of mind)…
Like the old tombstone inscription advises: “I am what you will be.” Be warned!
Interesting insights and interpretations here:
https://www.reddit.com/r/BLSP/comments/lijikq/due_diligence_warning_regarding_blue_sphere/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
Sources/documentation?
Lol. Yeah—I guess all their assets just dried up and evanesced. Oh wait, that’s right, their creditors seized them (speaking of lack of evidence!)…
I grasp what you said quite clearly (about timing), but I outlined a *different* and not better/worse set of principles that I also operate by. Sorry that a detailed argument can’t often be captured adequately in three lines. Lol
My gut tells me that was largely political: Joseph Schumpeter talks at length about the monopolistic tendencies of capitalism (which is, nonetheless, the best economic system yet seen in our imperfect world) in is his book “Capitalism, Socialism, and Democracy.”
Good to see you, friend!
Did Apple ever go down to .0002 and then proceed to R/S its way onto a more legitimate listing platform?
What REALLY chapped my backside was the fact that principally-interested players (potentially including such folks as Gershman and/or Saïd) we talking all over Twitter and other social media about the apparently high effectiveness of CaverStem—which, given the pervasive nature of the underlying medical problem, arguably contributed to a skyrocketing PPS from .002 to .07 in early 2018.
Meantime, the company itself, despite being in “commercialization” (their word) of CaverStem for about 3 years now, did precious little to promote clarity and conviction around their business model and plans—you know, the things that legitimate companies do to drive market cap and shareholder value (that is, when they have something majorly marketable in the first place).
Instead, within days of declaring that they “delivered” and appreciated the patience and trust shown by their shareholders, they announced the first R/S, which took effect in early 2020 (during “commercialization”). Over the next year + they again swelled the OS to over 1B, following which they essentially announced that they were going to R/S their way onto the NASDAQ: hence the 1:500 R/S that we saw last month, which was the SECOND in less than two years.
TWO: 1:150 in early 2020 (and it had NOTHING to do with COVID) and another 1:500 guy-punch this past December. That’s who you’re dealing with here…
Even at today’s “high” of 3.88, my split-adjusted PPS is .00005173.
NEVER FORGET…
The SEC filing in early December said that “Ichim and Patel resigned as directors of the company”: why would they relinquish any of the control over their company?
https://m.marketscreener.com/quote/stock/CREATIVE-MEDICAL-TECHNOLO-120792626/news/CREATIVE-MEDICAL-TECHNOLOGY-HOLDINGS-INC-Entry-into-a-Material-Definitive-Agreement-Notice-of-D-37239597/
I respect your charting savior faire for sure (I think I remember seeing you here at a few points in the past—including when it first ran up to .07 back in 2018).
If what you say is true about the fundamentals, then what are your thoughts on:
The progression of the “typical” OTC when it goes from this status to “fundamental” status (assuming that growth and development are organic, there shouldn’t be any “light switch moments”—rather developments should be traceable to some extent, which would mean that some meaningful measure of the fundamentals BECOMES very relevant). In other words, “nothing comes from nothing,”right?
These guys have shown themselves to be dabbling clowns (at best). Anyone who thought this was a long-term INVESTMENT got fleeced badly (and repeatedly). Now Ichim and Patel have left the building. This is a caricature in the extreme—but I’m glad to hang around and see them get “theirs”…
Those who view each day/week as a “new scene” never hold the managers—the stewards of their investment dollars—to account for nearly enough. The bottom line is that Warbington and Dickerson did nothing over 3+ years to drive the shareholder value in anything other than a manner that resulted in two R/Ss within as many years. They are still “on the bus,” while two of the biggest scientists have left the building…
TDA still won’t in the US…
Again, I’ll pose the following clear and logically simple question: why would Ichim and Patel—two cornerstones of the scientific foundation of this company—RESIGN (thereby ENDING their ability to collect additional shares) if some huge windfall was ANYWHERE in sight?
Worthless then, worthless now. “Business minds,” who drove this repeatedly into the ground worse than the Hindenburg, are also WORTHLESS.
At least that’s the last I knew. The PR in early December (in which the resignations of Ichim and Patel were announced) introduced some additional new names—but I’m not familiar with them.
Tim Warbington and Don Dickerson. Drs. Ichim and Patel resigned: why would they leave if some windfall was “just around the corner”?
Still more than -50% since most recent R/S—the second in fewer than as many years (and neither had ANYTHING to do with COVID and EVERYTHING to do with the same “management” team that’s there today—MINUS two of the big-named scientists).
Clown-level “business minds” are who they are. Four years have taught the careful, critical observer a lot…
I must confess a lack of surprise about your “non-answer answer” to a serious question.
If true, then why did arguably the two most important scientific researchers—Ichim and Patel—recently resign from the Board of Directors? Would they knowingly and willingly leave behind something that had significant scientific (and monetary) value?
Caveat emptor. My own share count went from 5+ MILLION to *69*—no, that’s not a typo. Do you want to be invested in a company that “values” its shareholders like that? If they had something that would really drive revenues and profits, why didn’t they release it at any point over the last 4 years? Consider yourself amply warned…
Only Spam and chopped liver served here. BUYER BEWARE…
https://ih.advfn.com/stock-market/NASDAQ/creative-medical-technol-CELZ/stock-news/86750370/current-report-filing-8-k
The 8-K, under “Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.”
It was in the news release in the first week of December—the one that talked about uplisting to NASDAQ
I complain when insiders pump the company on social media—then the mgmt drives the stock, through two R/Ss In less than two years, continuously into the ground. A court of law is likely to agree.
They’ve been hinting at that for at least 4 years (that I’m aware of).
Devil’s advocate: if some “rocket-to-the-moon” revenues were really expected based on FDA approvals, would Drs. Ichim and Patel—who were directly responsible for much of the science here—RESIGN from the company???
“Future” is being managed by the same “business minds” who drove this into the ground over the past 4 years—and for an encore, just this month drove off Drs. Ichim and Patel.
Again: what is left that will generate market-cap-improving REVENUES—or was even here in the first place?
A very simple question for CELZ (and anyone wishing to suggest that this company is worthy of consideration as a serious investment): how do they make their money?
Before, one might have thought that this came from the “science side of the house”—but now we see the recent resignation of two scientific cornerstones of the company—Drs. Ichim and Patel. Are we about to witness another corporate identity “switcheroo” (up until about 6 years ago they were known as “Jolley Marketing,” with ticker JLLM: https://fintel.io/n/us/jllm/creative-medical-health)?
So again, what are the core revenue-generating business activities of this company?